Researchers identified 4 classifier genes relevant to gastric cancer in 307 patients in an internal cohort.
Researchers are investigating the efficacy of surgical resection plus HIPEC for improving survival outcomes among patients with gastric cancer.
Researchers are evaluating the safety and efficacy of additional chemotherapy and radiation, alone or with surgery, among patients with esophageal or gastric cancer.
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
Researchers are evaluating the feasibility and safety of adjuvant HIPEC in patients with locally advanced gastric cancer.
In 2017, new treatment approaches for patients with esophagogastric cancer have been investigated, including novel neoadjuvant regimens and immunotherapies.
Researchers are evaluating the safety and efficacy of FOLFOX plus nab-paclitaxel as a first-line therapy for patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
Researchers are evaluating the safety and efficacy of PLX9486, a TKI of c-Kit, in combination with pexidartinib (PLX3397) and sunitinib among patients with GIST.
Researchers are investigating the efficacy of pembrolizumab immunotherapy plus chemotherapy as perioperative treatment for patients with gastric cancer or adenocarcinoma of the gastroesophageal junction.
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Neoadjuvant FLOT followed by surgery improves outcomes among patients with gastric or gastroesophageal junction cancer.
For this phase 2 trial, researchers are evaluating the efficacy and safety of andecaliximab (GS-5745) and nivolumab vs nivolumab alone.
Patients with operable gastroesophageal cancer with high microsatellite instability did not derive benefit from perioperative chemotherapy.
GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.
Bursectomy can be safely performed without increasing the risk of morbidity or mortality among patients with cT3 or cT4 gastric cancer.
The addition of everolimus to paclitaxel did not significantly improve overall response rate, progression-free survival, or overall survival.
For patients with advanced gastric cancer, second-line treatment with ramucirumab is safe and efficacious regardless of age.
Among patients with malignant gastric outlet obstruction caused by gastric cancer, surgical palliation was effective for maintaining patient quality of life.
Omitting surgery and using a watch-and-wait approach does not compromise outcomes for selected patients with advanced rectal cancer.
The FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401O.
Nivolumab (Opdivo) improved overall survival compared with placebo among patients with unresectable advanced or recurrent gastric cancer.
Mylan has submitted a biologics license application (BLA) for MYL-1401O, a proposed biosimilar trastuzumab, to the FDA.
Bayer submitted a supplemental New Drug Application to the FDA for regorafenib (Stivarga) as a second-line treatment.
Trifunctional antibodies such as catumaxomab may have a significant impact in treating these malignancies.
Study authors conclude that FLOT should be an internationally standard option for patients with resectable gastric cancer.
Adding ramucirumab to mFOLFOX6 therapy in an intent-to-treat population of patients with GEJ does not improve PFS.
Proton pump inhibitors (PPIs) may reduce the efficacy of capecitabine as a treatment for gastroesophageal cancer.
In patients with pathological stage (pStage) II or III gastric cancer, the number of retrieved lymph nodes (RLNs) is an independent poor prognostic factor.
Pembrolizumab may have a manageable toxicity profile and promising antitumor activity in patients with recurrent or metastatic PD-L1-positive gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma